monoethanolamine oleate
{{Short description|Pharmaceutical drug}}
{{Infobox drug
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 407803695
| IUPAC_name = 2-Hydroxyethylammonium oleate
| image = Structural formula of monoethanolamine oleate.svg
| drug_name = Ethanolamine Oleate
| tradename =
| Drugs.com = {{drugs.com|MTM|ethanolamine_oleate}}
| pregnancy_AU =
| pregnancy_US =
| pregnancy_category =
| legal_AU =
| legal_CA =
| legal_UK =
| legal_US =
| legal_status =
| routes_of_administration =
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
| excretion =
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 2272-11-9
| ATC_prefix = C05
| ATC_suffix = BB01
| PubChem = 5282489
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank = DB06689
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 4445632
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = U4RY8MRX7C
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D02276
| chemical_formula =
| C=20 | H=41 | N=1 | O=3
| density = 0.974
}}
Monoethanolamine oleate (ethanolammonium oleate) is an organic compound with the formula [CH3(CH2)7CH=CH(CH2)7CO2][H3NCH2CH2OH].. A colorless oily liquid, it is an example of a protic ionic liquid.{{cite journal | vauthors = Toledo Hijo AA, Maximo GJ, Costa MC, Cunha RL, Pereira JF, Kurnia KA, Batista EA, Meirelles AJ | display-authors = 6 | title = Phase Behavior and Physical Properties of New Biobased Ionic Liquid Crystals | journal = The Journal of Physical Chemistry B | volume = 121 | issue = 14 | pages = 3177–3189 | date = April 2017 | pmid = 28332847 | doi = 10.1021/acs.jpcb.7b01384 }} It is a salt formed by the reaction between monoethanolamine and oleic acid.{{cite journal |doi=10.1016/j.fluid.2010.08.022 |title=Synthesis and Thermophysical Properties of Two New Protic Long-Chain Ionic Liquids with the Oleate Anion |date=2010 | vauthors = Álvarez VH, Mattedi S, Martin-Pastor M, Aznar M, Iglesias M |journal=Fluid Phase Equilibria |volume=299 |pages=42–50 |url=http://www.repositorio.ufba.br/ri/handle/ri/5593 }}
Antivaricose agent
As an antivaricose agent, it is injected topically into varicosities to cause sclerosis (closure) of the abnormal vein. It is indicated for the treatment of patients with esophageal varices that have recently bled, to prevent rebleeding. Ethanolamine is not indicated for the treatment of patients with esophageal varices that have not bled. There is no evidence that treatment of this population decreases the likelihood of bleeding. Sclerotherapy with ethanolamine has no beneficial effect upon portal hypertension, the cause of esophageal varices, so that recanalization and collateralization may occur, necessitating reinjection.{{cite web |title=Ethanolamine Oleate |url=https://www.rxlist.com/ethamolin-drug.htm |website=RXList |access-date=7 March 2020}}
References
{{Reflist}}
{{Vasoprotectives}}
{{cardiovascular-drug-stub}}